Olodaterol (BI 1744)

DRUG5 trials

Sponsors

Boehringer Ingelheim

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 3

12 / 48 wk Pivotal PFT vs PBO in COPD II

CompletedNCT00782509

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2009-02-28Updated: 2014-06-27

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I

CompletedNCT00793624

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2009-02-28Updated: 2014-06-27

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

CompletedNCT00796653

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2009-01-31Updated: 2014-06-27

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

CompletedNCT01040130

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2010-01-31Updated: 2014-07-08

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

CompletedNCT01040793

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2010-01-31Updated: 2014-07-08

Related Papers

Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials.

2020-09-1738 citations

<p>A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD</p>

International Journal of COPD2020-08-017 citations

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat<sup>®</sup> device for maintenance treatment of COPD: comparison with the long-acting β<sub>2</sub>-agonist formoterol.

2017-10-238 citations

Effect of olodaterol once-daily on heart rate in GOLD 2–4 COPD patients

2017-09-01

Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies.

2016-07-0614 citations

One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis

COPD Journal of Chronic Obstructive Pulmonary Disease2015-02-1835 citations

The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.

2014-08-0934 citations

P230 Symptomatic benefit of olodaterol QD delivered via Respimat<sup>®</sup>vs placebo and formoterol BID in patients with COPD: combined analysis from two 48-week studies: Abstract P230 Table 1.

Thorax2013-11-141 citations